EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access · CC BY-NC-ND 4.0

Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study

Jan Wolf, Katrin Lorenz, Ahmed E Othman, Anna Beck, Helena M Michel, Lea Grauhan, Heike Elflein, Maximilian Luffy, Anja Eckstein, Harald Lahner, Michael Schittkowski, Maren Horn und 10 weitere

The Journal of Clinical Endocrinology & Metabolism · 22.04.2026 · 111 (5) · 1248-1257

DOI: 10.1210/clinem/dgaf655 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 09.12.2025. Verfasst von Jan Wolf und 21 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine I, Johannes Gutenberg University (JGU) Medical Center, Mainz 55101, Germany. Hauptthemen laut MEDLINE: Graves Ophthalmopathy, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharma AG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Interleukin (IL)-17, a key proinflammatory cytokine, drives inflammation and fibrosis in Graves orbitopathy (GO), and elevated IL-17 and Th17 cells correlate with disease activity and severity.

Objective

The ORBIT study aimed to evaluate the efficacy and safety of secukinumab, an IL-17A inhibitor, in individuals with active, moderate-to-severe GO.

Methods

A randomized, double-blind, placebo-controlled, parallel-group, multicenter trial was conducted. Adults with active, moderate-to-severe, non-sight–threatening GO randomly (1:1) received secukinumab 300 mg or placebo subcutaneously over a 16-week double-blind treatment period, followed by an additional 16-week open-label treatment phase for proptosis nonresponders. Safety parameters, thyroid-related hormones, and autoantibodies were also assessed. The primary end point was overall response of reduced Clinical Activity Score (CAS) of 2 or more points and a reduction of 2 mm or greater in proptosis from baseline without worsening in the fellow eye at week 16.

Results

Twenty-eight adult GO patients with a CAS of 4 or greater were enrolled (secukinumab, n = 14; placebo, n = 14). None in either the secukinumab or placebo group achieved an overall response at weeks 16 and 32, respectively, when all patients received open-label secukinumab. No clinically meaningful changes were observed in ophthalmic symptoms and signs, proptosis, lid aperture, eye muscle motility, CAS, and health-related quality of life either at week 16 or week 32. No meaningful effect on serum levels of thyroid-related hormones and antibodies was observed. Secukinumab was well tolerated, with mostly mild adverse events. Neither treatment-induced study discontinuation nor new safety signals were registered.

Conclusion

Secukinumab did not show clinical efficacy vs placebo when treating patients with active, moderate-to-severe GO.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Graves OphthalmopathyAntibodies, Monoclonal, HumanizedHumansDouble-Blind MethodFemaleMaleMiddle AgedAdultSeverity of Illness IndexInterleukin-17Treatment OutcomeAged

Stichwörter der Autor:innen

Graves orbitopathyORBIT trialactiveimmunosuppressive treatmentinterleukin-17Amoderate-to-severe GOsecukinumab

Substanzen

secukinumabAntibodies, Monoclonal, HumanizedInterleukin-17IL17A protein, human

Autor:innen und Institutionen

  • Department of Medicine I, Johannes Gutenberg University (JGU) Medical Center, Mainz 55101, Germany.
  • Department of Ophthalmology, JGU Medical Center, Mainz 55101, Germany.
  • Department of Neuroradiology, JGU Medical Center, Mainz 55101, Germany.
  • Clinic for Ophthalmology, University Clinic Essen, Essen 45147, Germany.
  • Clinic for Endocrinology, Diabetology and Metabolism, University Clinic Essen, Essen 45147, Germany.
  • Department of Ophthalmology, University Medicine Göttingen, Göttingen D 37085, Germany.

ORCID-Profile: George J Kahaly

Förderung

  • Novartis Pharma AG

Zitieren

APA

Wolf, J., Lorenz, K., Othman, A. E., Beck, A., Michel, H. M., Grauhan, L., Elflein, H., Luffy, M., Eckstein, A., Lahner, H., Schittkowski, M., Horn, M., Lagrèze, W. A., Bleul, T., Pitz, S., Vorländer, C., Pieterse, C. C., Porter, B., Clemens, A., …, & Kahaly, G. J. (2026). Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. The Journal of Clinical Endocrinology & Metabolism, 111(5), 1248-1257. https://doi.org/10.1210/clinem/dgaf655

Vancouver

Wolf J, Lorenz K, Othman AE, Beck A, Michel HM, Grauhan L, et al. Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study. The Journal of Clinical Endocrinology & Metabolism. 2026;111(5):1248-1257. doi:10.1210/clinem/dgaf655

BibTeX
@article{Wolf2026,
  author = {Wolf, Jan and Lorenz, Katrin and Othman, Ahmed E and Beck, Anna and Michel, Helena M and Grauhan, Lea and Elflein, Heike and Luffy, Maximilian and Eckstein, Anja and Lahner, Harald and Schittkowski, Michael and Horn, Maren and Lagrèze, Wolf A and Bleul, Tim and Pitz, Susanne and Vorländer, Christian and Pieterse, Christelle C and Porter, Brian and Clemens, Andreas and Draikiwicz, Steven and Reinhardt, Maximilian and Kahaly, George J},
  title = {Secukinumab in Moderate-to-Severe Graves Orbitopathy: A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2026},
  volume = {111},
  number = {5},
  pages = {1248--1257},
  doi = {10.1210/clinem/dgaf655}
}
Kostenlos starten →